When does farxiga go off patent?

Farxiga Patent Expiry and Biosimilars

Farxiga, also known as dapagliflozin, is an oral diabetes medication developed by AstraZeneca. It's a popular treatment for type 2 diabetes and has also been approved for use in chronic kidney disease.

Patent Status

According to DrugPatentWatch.com, the farxiga patent expired in the United States on July 11, 2022 [1]. This means that biosimilar versions of the drug, produced by other manufacturers, are now eligible for approval and sale in the country.

Biosimilar Market Entry

However, it's essential to note that market entry for biosimilars, including Farxiga, often involves a complex process of regulatory approval and may take time. Biosimilar manufacturers must show that their product is highly similar to the original version while demonstrating equivalent safety and efficacy [2].

Patent Expiration in Other Regions

The patent expiration date may vary in different regions. For instance, in Europe, the farxiga patent expires on July 8, 2024, and in Canada, it expires on May 24, 2024 [3].

Impact on Patients and Healthcare

As Farxiga goes off patent, patients may experience increased access to more affordable versions of the medication, which could potentially improve adherence to treatment plans. Healthcare providers may also consider switching patients to more affordable options, which could help reduce healthcare costs.

References

[1] DrugPatentWatch.com: Dapagliflozin - Patent Expiration Date (2022)

[2] FDA.gov: Guidance for Industry: Biosimilarity and Interchangeability Evaluations

[3] Patently Biotech: AstraZeneca's Farxiga patent expires in EU and other regions